Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Phase 2
Not yet recruiting
- Conditions
- Crohn's DiseaseUlcerative Colitis
- Interventions
- Drug: Zasocitinib
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 183
- Registration Number
- NCT06764615
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 3
Not yet recruiting
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT06747351
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
Phase 2
Not yet recruiting
- Conditions
- Dengue Fever
- Interventions
- Biological: TDVOther: Placebo
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 186
- Registration Number
- NCT06741683
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Phase 3
Not yet recruiting
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Drug: MezagitamabDrug: Placebo
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 171
- Registration Number
- NCT06722235
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Not yet recruiting
- Conditions
- Cytomegalovirus (CMV)
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 75
- Registration Number
- NCT06677892
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Phase 3
Not yet recruiting
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: ZasocitinibDrug: Placebo
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT06671496
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Phase 3
Not yet recruiting
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: ZasocitinibDrug: Active ComparatorDrug: Placebo
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1088
- Registration Number
- NCT06671483
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Phase 3
Not yet recruiting
- Conditions
- Dengue Fever
- Interventions
- Other: PlaceboBiological: TDV
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 212
- Registration Number
- NCT06665035
- Locations
- 🇨🇴
Clinica de la Costa, Barranquilla, Atlantico, Colombia
🇨🇴Centro de Estudios en Infectología Pediátrica S.A.S - CEIP S.A.S, Cali, Valle Del Cauca, Colombia
🇹🇭Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
Recruiting
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06615921
- Locations
- 🇦🇹
Medical University of Vienna Dept. of Nephrology and Dialysis, Vienna, Austria
🇩🇰Copenhagen University Hospital, Rigshospitalet, Copenaghen, Denmark
🇫🇷Groupe Hospitalier Pellegrin - CHU BORDEAUX, Bordeaux, France
A Study of TAK-951 in Healthy Adults
Phase 1
Terminated
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboDrug: TAK-951
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 48
- Registration Number
- NCT06610279
- Locations
- 🇺🇸
ICON, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath